Chemistry: analytical and immunological testing – Cancer
Patent
1998-08-25
1999-11-30
Warden, Jill
Chemistry: analytical and immunological testing
Cancer
436 63, 436 71, 436161, 436162, 436103, 436104, 436105, 436177, G01N 3350
Patent
active
059941413
ABSTRACT:
Methods for diagnosing and screening for ovarian carcinomas in a subject are provided The methods employ the steps of preparing a plasma sample from a blood specimen from the subject, and assaying for the presence of lysophosphatidic acid in the plasma sample. The presence of lysophosphatidic acid in the plasma sample is indicative of ovarian carcinoma in the subject. In a preferred embodiment the plasma sample is prepared under conditions which minimize the release of lysophosphatidic acid from platelets in the blood specimen into the plasma.
REFERENCES:
patent: 4999344 (1991-03-01), Jett-Tilton, et al.
patent: 5277917 (1994-01-01), Xu et al.
patent: 5326690 (1994-07-01), Xu et al.
patent: 5595738 (1997-01-01), Pomato et al.
patent: 5824555 (1998-10-01), Xu et al.
Xu et al. "Activation of Human Ovarian cancer cells: role of lipid factors in ascitic fluid" Ovarian Cancer 3--Chapter 13, p. 121-134, 1994.
Xu et al. "Lysophospholipids activate ovarian & breast cancer cells". Biochem. J. (1995), 309 933-940.
Xu et al. "Characterization of an Ovarian Cancer Activating Factor in Ascities from Ovarian Cancer Patients", Clinical Cancer Research vol. 1, 1223-1232, Oct. 1995.
Xu et al. Effect of Lysophospholipids on Signaling in the Human Jurical T Cell Line: Journal of Cellular Physiology 163:441-450, 1995.
Moolenaar, W. "Lysophospholidic acid signalling". Current Opinion in Cell Biology; 7:203-210, 1995.
Moolenaar, W. "LPA: a novel lipid mediator with diverse biological actions". Trends in Cell Biology, 4, 213-218, 1994.
Eichholtz et al "The Bioactive phospholipid lysoplasphatidic acid is released from activated platelets". Biochem J. 291, 677-680, 1993.
Jalink et al. "Growth Factor-Like effects of lysophospholidic acid a novel lipid mediator". Biochimica of Biophysica Acta, 1198; 185-196, 1994.
"Lysophophatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity" by Fang, et al., The Journal of Biological Chemistry, vol. 272, No. 21, May 23, 1997, pp. 13683-13689.
"Peptide and Lipid Growth Factors Decrease cis -Diamminedichloroplatinum-induced Cell Death in Human Ovarian Cancer Cells" by Frankel, et al., Clinical Cancer Research, vol. 2, Aug. 2996, pp. 1307-1313.
"A Pueative New Growth Factor in Ascitic Fluid form Ovarian Cancer Patients: Identification, Characterization, and Mechanism of Action" by Mills, et al., Cancer Research, 42, Mar. 1, 1998, pp. 1066-1071.
"Ascitic Fluid from Ovarian Cancer Patients Contains Growth Factors Necessary for Intraperitoneal Growth of Human Ovarian Adenocarcinoma Cells" by Mills, et al., J. Clin. Invest., vol. 86, Sep. 1990, pp. 851-855.
"Levels of soluble interleukin-2 receptor-.alpha. are elevated in serum and ascitic fluid from epithelial ovarian cancer patients" by Hurteau, et al., Am J. Obstet Gynecol, vol. 170, No. 3, Mar. 1994, pp.918-928.
"Soluble Interleukin-2 Receptor Alpha is Elevated in Sera of Patients with Benign Ovarin Neoplasms and Epithelial Ovarian Cancer" by Hurteau, et al., Cancer, vol. 76, No. 9, Nov. 1, 1995, pp. 1615-1620.
"Induction of In Vitro Tumor Cell Invasion of Cellular Monoplayers by Lysophosphatidic Acid or Phospholipase D" by Imamura, Biochemical and Biophysical Research Communications, Vo. 193, No. 2, Jun. 15, 1993, pp. 497-503.
"Analysis of the Proliferative Response to Lysophosphatidic Acid in Primary Cultures of Mammary Epithelium: Differences between Normal and Tumor Cells" by Imagawa, et al., Experimental Cell Research, 216, pp. 178-186 (1995).
"Role of Growth Factors: Their Receptors and Signalling Pathways in the Diagnosis, Prognosis, Follow-up and Therapy of Ovarian Cancer" by Mills, et al. Diagnostic Oncology, 1992, 2:39-54.
"Lysophosphatidic acid: G-protein signalling and cellular responses" by Moolenaar, Cell Regulation, pp. 168-173.
Abstract #710, "Lysophosphatidic acid, a diagnostic biomarker for ovarian and other gynecological cancers" by Xu, et al., Proceedings of the American Association for Cancer Research, vol. 38, Mar. 1997, p. 106.
"Increased phophatidic acid and decreased lysophosphatidic acid in response to thrombin is associated with inhibition of platelet aggregation" by Gerrard, et al., Biochem Cell Bio., vol. 71, 1993, pp. 432-439.
"LPA: a novel lipid mediator with diverse biological actions" by Moolenaar, Trends in Cell Biology, vol. 4, Jun. 1994, pp. 213-218.
"Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger" by Moolenaar, The Journal of Biological Chemistry, vol. 270, No. 22, Jun. 2, 1995, pp. 12949-12952.
"Lysophosphatidic acid possesses dual action in cell proliferation" by Tigyi, et al. Proc. Natl. Acad. Sci. USA, vol. 91, Mar. 1994, pp. 1908-1912.
"Decanol lysophosphatidic acid induces platelet aggregation through an extracellular action" by Watson, et al., Biochem. J., (1985) 232, pp. 61-66.
"Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers" by Xu, et al., The Journal of the American Medical Association, vol. 280, No. 6 Aug. 26, 1996, pp. 719-723.
"Phorbol 12-Myristate 13-Acetate Stimulates Lysophosphatidic Acid Secretions from Ovarian and Cervical Cancer Cells but not from Breast or Leukemia Cells" by Shen, et al., Gynecologic Oncology, 71, pp. 364-368 (1998).
"Elevated Levels and Altered Fatty Acid Composition of Plasma Lysophosphatidylcholine (LYSOPC) in Ovarian Cancer Patients" by Okita, et al., Int. J. Cancer, 71, 31-34 (1997).
"Malignant effusions contain lysophosphatidic acid (LPSA)-like activity" by Westermann, et al., Annals of Oncology, 9, pp. 437-442 (1998).
Casey Graham
Gaudette Douglas C.
Holub Bruce J.
Mills Gordon B.
Xu Yan
Carrillo S.
The Cleveland Clinic Foundation
Warden Jill
LandOfFree
Method of detecting gynecological carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of detecting gynecological carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of detecting gynecological carcinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1670755